Immunocore Holdings plc ADR(IMCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.35 | Insider Own | 0.96% | Shs Outstand | 51.5M | Perf Week | -1.96% |
| Market Cap | 1.65B | Forward P/E | - | EPS next Y | -1012.44% | Insider Trans | - | Shs Float | 51.0M | Perf Month | 4.31% |
| Enterprise Value | 1.20B | PEG | - | EPS next Q | -0.13 | Inst Own | 95.61% | Short Float | 15.3% | Perf Quarter | -4.37% |
| Income | -0.02B | P/S | 3.83 | EPS this Y | 92.46% | Inst Trans | -4.9% | Short Ratio | 18.18 | Perf Half Y | 11.01% |
| Sales | 0.43B | P/B | 3.94 | EPS next 5Y | 65.03% | ROA | -1.64% | Short Interest | 7.80M | Perf YTD | -7.92% |
| Book/sh | 8.11 | P/C | 1.87 | EPS past 3/5Y | - | ROE | -4.47% | 52W High | -21.5% ($40.71) | Perf Year | -4.48% |
| Cash/sh | 17.09 | P/FCF | - | Sales past 3/5Y | 31.32% 59.68% | ROIC | -2.12% | 52W Low | 16.22% ($27.50) | Perf 3Y | -25.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | 98.06% | Volatility(W/M) | 3.64% 3.93% | Perf 5Y | -15.74% |
| Dividend TTM | - | EV/Sales | 2.79 | Sales Y/Y TTM | 20.19% | Oper. Margin | -5.24% | ATR (14) | 1.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.44 | EPS Q/Q | 92.33% | Profit Margin | -4.2% | RSI (14) | 55.76 | Recom | 1.64 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.47 | Sales Q/Q | 17.1% | SMA20 | 6.09% ($30.13) | Beta | 0.82 | Target Price | $64.17 |
| Payout | - | Debt/Eq | 1.04 | Earnings | 2026/8/6 | SMA50 | -2.15% ($32.66) | Rel Volume | 0.73 | Prev Close | $31.28 |
| Employees | 524 | LT Debt/Eq | 1.03 | EPS/Sales Surpr. | -306.19% 5.03% | SMA200 | 0.56% ($31.78) | Avg Volume(3M) | 0.43M | Price | $31.96 |
| IPO | 2021/2/5 | Option/Short | Yes/Yes | Trades | 3494 | Volume | 314,119 | Change | 2.17% |
🧬 Immunocore Holdings is a commercial-stage biotech company developing oncology, infectious disease, and autoimmune therapies based on its proprietary ImmTAX (ImmTAC) T-cell receptor bispecific antibody platform. Its first approved drug, KIMMTRAK (tebentafusp), is a treatment for metastatic uveal melanoma and is marketed in the United States and Europe, forming the company's current revenue base. Headquartered in the US and UK, the company is expanding its global clinical pipeline.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
IMCR has weak earning power
Of every $100 in sales, $5.24 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +92.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $383. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -15.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 95.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #122 of 594 in the industry
Based on market cap of $2B.
URGN#119 UroGen Pharma Ltd $2B PER - 
NVAX#120 Novavax Inc $2B PER - 
RARE#121 Ultragenyx Pharmaceutical Inc $2B PER - IMCR#122 Immunocore Holdings plc ADR $2B PER - 
TRAX#123 First Tracks Biotherapeutics Inc $2B PER - 
FAQ
What kind of company is IMCR?
IMCR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMCR?
The market cap of IMCR is approximately $1.6B, ranking 2,226 within its sector.
What is the 52-week high and low for IMCR?
IMCR has recorded a 52-week high of $40.71 and a low of $27.50.
